Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Nat Biotechnol ; 21(4): 414-21, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12612588

RESUMO

Delivery of protein therapeutics often requires frequent injections because of low activity or rapid clearance, thereby placing a burden on patients and caregivers. Using glycoengineering, we have increased and prolonged the activity of proteins, thus allowing reduced frequency of administration. Glycosylation analogs with new N-linked glycosylation consensus sequences introduced into the protein were screened for the presence of additional N-linked carbohydrates and retention of in vitro activity. Suitable consensus sequences were combined in one molecule, resulting in glycosylation analogs of rHuEPO, leptin, and Mpl ligand. All three molecules had substantially increased in vivo activity and prolonged duration of action. Because these proteins were of three different classes (rHuEPO is an N-linked glycoprotein, Mpl ligand an O-linked glycoprotein, and leptin contains no carbohydrate), glycoengineering may be generally applicable as a strategy for increasing the in vivo activity and duration of action of proteins. This strategy has been validated clinically for glycoengineered rHuEPO (darbopoetin alfa).


Assuntos
Sistemas de Liberação de Medicamentos/métodos , Glicoproteínas/biossíntese , Glicoproteínas/genética , Engenharia de Proteínas/métodos , Proteínas/uso terapêutico , Anemia/tratamento farmacológico , Animais , Células CHO/metabolismo , Células COS/metabolismo , Cricetinae , Eritropoetina/genética , Eritropoetina/metabolismo , Eritropoetina/uso terapêutico , Excipientes/química , Feminino , Melhoramento Genético/métodos , Glicoproteínas/metabolismo , Humanos , Leptina/biossíntese , Leptina/deficiência , Leptina/genética , Leptina/uso terapêutico , Camundongos , Camundongos Endogâmicos BALB C , Proteínas/administração & dosagem , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/genética , Proteínas Recombinantes/uso terapêutico , Trombopoetina/biossíntese , Trombopoetina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA